Overcoming Affinity and Expression Bottlenecks in TCR Discovery
Supported by:
22 October 2025
3:00pm
Shares
- Like
- Digg
- Del
- Tumblr
- VKontakte
- Buffer
- Love This
- Odnoklassniki
- Meneame
- Blogger
- Amazon
- Yahoo Mail
- Gmail
- AOL
- Newsvine
- HackerNews
- Evernote
- MySpace
- Mail.ru
- Viadeo
- Line
- Comments
- Yummly
- SMS
- Viber
- Telegram
- Subscribe
- Skype
- Facebook Messenger
- Kakao
- LiveJournal
- Yammer
- Edgar
- Fintel
- Mix
- Instapaper
- Copy Link
Low affinity or poor TCR yields slowing you down? Explore how CHO expression of soluble TCRs and TCR affinity maturation workflows via phage, serving as essential building blocks for early-stage TCR-TCE candidate generation.
T cell receptor-T cell engagers (TCR-TCEs) are gaining momentum as a targeted therapeutic strategy, but key challenges still limit early-stage discovery. Many researchers face issues like:
- Low-affinity TCRs from phage libraries
- Poor expression yields of soluble TCRs (sTCRs)
- Reliance on E. coli refolding, leading to high endotoxin
- Limited throughput for TCR candidate screening
- Lack of internal expertise to build next-gen TCR-TCEs
Join this webinar to explore two integrated strategies to overcome these challenges:
- High-titer CHO-based expression of sTCRs (~100 mg/L), enabling scalable and high-throughput production
- Optimized phage display affinity maturation, improving TCR binding by up to ~10,000-fold.
Dr. Wu will share real-world case studies and practical guidance for combining these workflows to improve TCR developability, serving as building blocks for a range of formats, including TCR-TCEs.
“If you’re still refolding TCRs in E. coli, it’s time for an upgrade.” – Dr. Wu
Whether you’re starting a new TCR program or optimizing an existing platform, this session will offer actionable strategies to accelerate discovery and improve candidate quality.
Register your details today >>
SPEAKER
Jiansheng Wu, Ph.D. – Senior VP, Head of CRO Services
Dr. Wu is the Head of CRO Services and Senior VP at WuXi Biologics. With vast experience and expertise in protein sciences, he has been instrumental in establishing global protein production facilities and developing cutting-edge technologies. Having participated in over 50 drug development projects, Dr. Wu is a leading authority in automated expression, purification, and characterization of diverse proteins. Previously at Genentech for 15 years, he made significant contributions to innovative protein expression and purification technologies.
Key learning points
- Learn about CHO-based expression methods for producing soluble TCRs at high titers (~100 mg/L), including formats relevant to TCR-TCEs
- Understand how phage display-based affinity maturation can be used to improve TCR binding affinity by up to ~10,000-fold (from 10–100 μM)
- Explore how expression and affinity maturation workflows can be integrated to support generation of TCR candidates for TCR-TCE development.
FAQs
Is the webinar free?
Yes – there is no charge to watch the webinar, either live or on-demand.
When will the webinar take place?
The webinar will take place live on 22 October 16:00 PM BST.
I’m busy. Can I watch it later?
The webinar will become available to watch on-demand shortly after the live webinar takes place.
What are the benefits of attending live?
During the live webinar, you’ll be able to ask the speakers your questions, which will then be answered during the live Q&A session towards the end of the webinar.
How long will the webinar be?
This webinar will last for up to one hour.
What do I need to watch this webinar?
All you need is a computer with an internet connection. Be sure to use headphones if in an office environment.
Do I receive a certificate?
Yes, you will receive a certificate if you attend the webinar live. The certificate will be sent with your on-demand video link.
